On April 19, Beijing YiChuang Biotechnology Industry Research Institute was unveiled in Beijing YiZhuang biomedical park. Mr. Fang zhining, the chairman of Zhongyuan company, attended the ceremony as the sponsor and director of the institute and awarded the first batch of 23 research institutes established on the platform of the Research Institute. Zhongyuan Company participated in the formation of the Biotechnology Process Research Institute, which is in the list of awarded research institutes.

In order to implement the State Council's "National Innovation Driven Development Strategy Outline" and implement the spirit of the National Science and Technology Innovation Conference, the Biotechnology Industry Research Institute was officially approved by the Beijing Civil Affairs Bureau on March 21, 2016. By integrating the resources of the industrial chain, pooling the talents of production, education and research, and relying on the development model of innovative research and development, technology transfer and achievement transformation industry, we will establish a one-stop technology platform connecting the frontier innovation of technology and technology industrialization. Relying on the advantages of platform services and innovation clusters, we have cultivated a number of research institutions with national and municipal scientific research projects as the subject.

The Bioprocess Research Institute is such a research institution rooted in the technology platform of the bio-industry industry. The research team led by Mr. Zhu Xican, the chief scientist of Zhongyuan Company, is responsible for solving the preparation of experimental samples of pyrogen-free animals in the development of innovative drugs, demonstrating the efficacy and safety, and providing the necessary technological solutions for the industrialization of experimental results. At present, the institute has made breakthroughs in the direction of genetic technology transformation and industrial common process, and has established long-term strategic cooperation with internationally renowned industrial process product manufacturers such as Sartorius, GE Healthcare and Filtrox. 

The Bioprocess Research Institute can achieve such results, relying on the talents of Zhongyuan Company for many years. Mr. Zhu Xican, head of the R&D team, worked at the Institute of Process Engineering of the Chinese Academy of Sciences and GE Healthcare. He was responsible for the production technology projects of several research institutes, the AKTA Retraining Program for GE Healthcare and the first WAVE product line manager. At present, the R&D team consists of 17 members, all of whom are graduates with a master's degree in biotechnology.

Beijing Yichuang Biotechnology Industry Research Institute is a new soil in China's biomedical industry. The establishment of the Biotechnology Process Research Institute is a new step in the development path of Zhongyuan Company. In the future, Zhongyuan Company will continue to adhere to the tenet of “professional service, assisting science and technology” and “to promote the cause of life science and serve the health of all mankind” as our mission. All Zhongyuan people will continue to uphold the values of unity, diligence, innovation and development, and make unremitting efforts on the road of transforming Chinese scientific research achievements and leading the upgrading of biological industries.